Boston Scientific Corporation (FRA:BSX)
86.60
-0.20 (-0.23%)
At close: Nov 28, 2025
Boston Scientific Revenue
Boston Scientific had revenue of $5.07B USD in the quarter ending September 30, 2025, with 20.34% growth. This brings the company's revenue in the last twelve months to $19.35B, up 21.62% year-over-year. In the year 2024, Boston Scientific had annual revenue of $16.75B with 17.61% growth.
Revenue (ttm)
$19.35B
Revenue Growth
+21.62%
P/S Ratio
7.81
Revenue / Employee
$365.09K
Employees
53,000
Market Cap
128.81B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.75B | 2.51B | 17.61% |
| Dec 31, 2023 | 14.24B | 1.56B | 12.29% |
| Dec 31, 2022 | 12.68B | 794.00M | 6.68% |
| Dec 31, 2021 | 11.89B | 1.98B | 19.92% |
| Dec 31, 2020 | 9.91B | -822.00M | -7.66% |
| Dec 31, 2019 | 10.74B | 912.00M | 9.28% |
| Dec 31, 2018 | 9.82B | 775.00M | 8.57% |
| Dec 31, 2017 | 9.05B | 662.00M | 7.89% |
| Dec 31, 2016 | 8.39B | 909.00M | 12.16% |
| Dec 31, 2015 | 7.48B | 97.00M | 1.31% |
| Dec 31, 2014 | 7.38B | 237.00M | 3.32% |
| Dec 31, 2013 | 7.14B | -106.00M | -1.46% |
| Dec 31, 2012 | 7.25B | -373.00M | -4.89% |
| Dec 31, 2011 | 7.62B | -184.00M | -2.36% |
| Dec 31, 2010 | 7.81B | -382.00M | -4.67% |
| Dec 31, 2009 | 8.19B | 138.00M | 1.71% |
| Dec 31, 2008 | 8.05B | -307.00M | -3.67% |
| Dec 31, 2007 | 8.36B | 536.00M | 6.85% |
| Dec 31, 2006 | 7.82B | 1.54B | 24.48% |
| Dec 31, 2005 | 6.28B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.87B |
| Siemens Healthineers AG | 23.38B |
| Fresenius SE & Co. KGaA | 22.45B |
| Merck KGaA | 21.27B |
| Fresenius Medical Care AG | 19.64B |
| Sartorius Aktiengesellschaft | 3.52B |
| Redcare Pharmacy NV | 2.82B |
| Fielmann Group AG | 2.42B |
Boston Scientific News
- 9 days ago - BSX Quantitative Stock Analysis - Peter Lynch - Nasdaq
- 10 days ago - Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know - Nasdaq
- 10 days ago - Boston Scientific (BSX) Down 5.7% Since Last Earnings Report: Can It Rebound? - Nasdaq
- 12 days ago - Boston Scientific (BSX) Announces 2026 Compensation Plans to Drive Performance and Shareholder Value - GuruFocus
- 13 days ago - BSX's Neuromodulation Prospect Looks Strong: What's Behind It? - Nasdaq
- 13 days ago - $100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today - Benzinga
- 13 days ago - Boston Scientific Corporation (BSX) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Zacks Industry Outlook Highlights Boston Scientific, Insulet, BioLife Solutions and Allurion - Nasdaq